After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Pacira BioSciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Pacira BioSciences Inc is $981.78M. A total of 0.67 million shares were traded on the day, compared to an average of 638.09K shares.
In the most recent transaction, Ceesay Abraham sold 2,354 shares of PCRX for 27.19 per share on Sep 04 ’25. After the transaction, the Director now owns 9,039 company shares. In a previous transaction on Sep 04 ’25, Ceesay Abraham bought 2,354 shares at 27.19 per share.
Among the insiders who sold shares, BIGAL MARCELO disposed of 4,912 shares on Aug 07 ’25 at a per-share price of $23.67. This resulted in the Director holding 11,393 shares of PCRX after the transaction. In another insider transaction, BIGAL MARCELO bought 4,912 shares at $23.67 per share on Aug 07 ’25.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, PCRX has a high of $27.64 and a low of $16.00.
As of this writing, PCRX has an earnings estimate of $0.65 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of $0.71 per share and a lower estimate of $0.62. The company reported an EPS of $0.79 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $16.88, while its Total Shareholder’s Equity was $730.41M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Buy with a score of 3.43.
